Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Checkpoint Inhibitors Herald New Era in Urothelial Cancer

January 9th 2019

Immune checkpoint inhibitors, with their favorable safety and antitumor activity profiles, have heralded a new era in urothelial carcinoma treatment.

UGN-101 Shows Encouraging CR Rates in Urothelial Cancer

January 9th 2019

The investigational mitomycin formulation UGN-101 demonstrated a 57% complete response rate in patients with low-grade upper-tract urothelial cancer.

Bellmunt Addresses Immunotherapy Advances, Challenges in Bladder Cancer

January 8th 2019

Joaquim Bellmunt, MD, PhD, provides insight on how to navigate the complex treatment paradigm of metastatic bladder cancer.

Dr. Somer on Treatment Selection Considerations in RCC

January 8th 2019

Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses treatment selection considerations in renal cell carcinoma (RCC).

Dr. Bellmunt Highlights Immunotherapy Options in Bladder Cancer

January 4th 2019

Joaquim Bellmunt, MD, PhD, genitourinary oncologist, Beth Israel Deaconess Medical Center, associate professor of medicine, Harvard Medical School, differentiates between immunotherapy options available for the treatment of patients with in bladder cancer.

Dr. Agarwal on Second-Line Therapy Selection in Metastatic RCC

January 4th 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma.

Treatment-Related AEs Can Require Careful Management in Patients With RCC

January 3rd 2019

Heather Greene, NP, discusses the importance of open communication between patients and providers from the onset of therapy and provided insight on the management of treatment-related adverse events in metastatic renal cell carcinoma.

Optimizing Combinations Next Challenge in mRCC

December 20th 2018

Bradley G. Somer, MD, discusses the potential of combination regimens for patients with metastatic renal cell carcinoma.

Choueiri Highlights Advances and Next Steps in RCC

December 18th 2018

Toni K. Choueiri, MD, discusses recent progress in RCC and where future research is heading in the field.

Dr. George on Sequencing in Renal Cell Carcinoma

December 18th 2018

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequencing in renal cell carcinoma (RCC).

Dr. Grivas on Mechanisms of Immune Response in Bladder Cancer

December 18th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses mechanisms of immune response in bladder cancer.

Expert Reflects on Recent Pivotal Data in RCC

December 18th 2018

Daniel J. George, MD, discusses the status of treatment for patients with high-risk stage III RCC, as well as the role of sunitinib (Sutent) and checkpoint inhibitors in the RCC paradigm.

Dr. Pal on Developments in Frontline Treatments for Patients With mRCC

December 15th 2018

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses developments made in frontline treatment for patients with metastatic renal cell carcinoma (mRCC).

CARMENA Data Leave Unanswered Questions in mRCC

December 14th 2018

Paul R. Eber, MD, discusses how the findings from CARMENA impact metastatic renal cell carcinoma treatment and what challenges remain.

Powles Navigates Rapidly Evolving Frontline Paradigm in Urothelial Carcinoma

December 13th 2018

Thomas Powles MBBS, MRCP, MD, discusses the changes to the frontline landscape of bladder cancer and where research should focus moving forward.

Dr. Eber on the Utility of Cytoreductive Nephrectomy in mRCC

December 12th 2018

Paul Eber, MD, urologist, The Conrad Pearson Clinic, discusses the utility of cytoreductive nephrectomy in metastatic renal cell carcinoma (mRCC).

Dr. Choueiri on Next Steps for Treatment in RCC

December 12th 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses next steps for treatment in renal cell carcinoma.

Landmark Trial Puts Robotic Surgery to the Test in Bladder Cancer

December 12th 2018

Vivek Venkatramani, MD, and Dipen J. Parekh, MD, discuss the evolution of surgery in bladder cancer.

Immunotherapy Changes Early-Stage Urothelial Carcinoma Paradigm

December 11th 2018

Newer immunotherapy agents are changing traditional strategies for care, resulting in higher levels of collaboration.

Common Treatment-Related Toxicities in mRCC

December 11th 2018

Heather Greene, a nurse practitioner at West Cancer Center, discusses common treatment-related toxicities in metastatic renal cell carcinoma (RCC).